- Cardiovascular diseases in HIV patients
-
Chang HH
- KMID: 2532274
- Cardiovasc Prev Pharmacother.
- 2022 Jul;4(3):95-98.
- doi: 10.36011/cpp.2022.4.e14
New and more effective antiretroviral therapy regimens have increased viral suppression and improved immune function recovery, leading to the extension of the lifespan of people living with HIV (PLWH). The... -
- CITED
-
- Close
- SHARE
-
- Close
- Severe hypoglycemia as a risk factor for cardiovascular outcomes in patients with type 2 diabetes: is it preventable?
-
Ko SH
- KMID: 2532276
- Cardiovasc Prev Pharmacother.
- 2022 Jul;4(3):106-113.
- doi: 10.36011/cpp.2022.4.e13
Hypoglycemia in people with type 2 diabetes mellitus (T2DM) is troublesome and an important barrier to diabetes management. Although more intensive glycemic control is emphasized to prevent diabetes-related long-term complications,... -
- CITED
-
- Close
- SHARE
-
- Close
- Blood pressure control in hypertensive disorders of pregnancy
-
Rismiati H, Lee HY
- KMID: 2532275
- Cardiovasc Prev Pharmacother.
- 2022 Jul;4(3):99-105.
- doi: 10.36011/cpp.2022.4.e16
Hypertension is a major cause of maternal morbidity and occurs as a complication in up to one in ten pregnancies. Hypertensive disorders of pregnancy encompass gestational hypertension, preeclampsia, chronic hypertension,... -
- CITED
-
- Close
- SHARE
-
- Close
- Effect of the addition of thiazolidinedione to sodium-glucose cotransporter 2 inhibitor therapy on lipid levels in type 2 diabetes mellitus: a retrospective study using Korean National Health Insurance Service data
-
Park T, Han K, Shin D, Park J
- KMID: 2532277
- Cardiovasc Prev Pharmacother.
- 2022 Jul;4(3):114-122.
- doi: 10.36011/cpp.2022.4.e15
Background: Dyslipidemia is common in patients with type 2 diabetes mellitus (T2D) and contributes to an increased risk of cardiovascular disease. Previous studies have shown that treatment with thiazolidinediones (TZDs)... -
- CITED
-
- Close
- SHARE
-
- Close
